施多宁、佳息患联合治疗与国产药去羟肌苷散、司他夫定和奈韦拉平三联治疗艾滋病的疗效比较

Comparision of the curative effects of efavirenz/indinavir and didanosine/stavudine/ nevirapine in HIV infected patients

目的比较施多宁、佳息患联合治疗与国产药物去羟肌苷散、司他夫定和奈韦拉平三药联合治疗人类免疫缺陷病毒(HIV)感染者1年时的疗效及不良反应。方法HIV感染者分为2组,一组26例,给予施多宁、佳息患联合治疗;另一组(对照组)38例,给予国产药物去羟肌苷散、司他夫定和奈韦拉平3药联合治疗,均随访1年,监测患者的血浆病毒载量及CD4+T淋巴细胞计数,并评价药物不良反应。结果经过1年治疗两组患者血浆中HIV RNA含量均明显降低,CD4+T淋巴细胞数量增加,药物不良反应轻微。结论施多宁、佳息患联合治疗组和国产药物三联治疗组在一年的观察中均能有效抑制HIV病毒的复制,机体免疫功能也有所改善。两组疗效和不良反应的差别无显著性意义。

Purpose To compare the curative effects and side effects between the combined efavirenz and indinavir therapy and the combined didanosine, stafudine and neverapine after the first 12 months. Methods Twenty-six HIV-infected individuals were treated with efavirenz and indinavir combined therapy. Similarily, 38 HIV-infected individuals were treated with didanosine, stafudine and neverapine. All cases were followed up for 12 months. The plasma HIV-1 RNA level and CD4 T cell count of the patients were measured at the beginning of treatment and the end of the twelfth month. Adverse events were also monitored in both groups. Results The plasma HIV-1 RNA was significantly decreased （P〈0.01）, and CD4 cell count was significantly increased （P〈0.01） in both groups. The adverse effects of didanosine, stafudine and neverapine were mild during the first 12 months. Conclusions After the first 12 month, there is no stastistically significant difference in thetherapeutic effects and adverse effects between efavirenz / indinavir group and didanosine/ stavudine/ nevirapine group. The replication of HIV is reduced and immunological function is improved in both groups.